Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

ABSTRACT: This phase II trial studies how well v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor MK2206 works in treating patients with previously treated colon or rectal cancer that has spread from the primary site to other places in the body or nearby tissue or lymph nodes and cannot be removed by surgery. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

DISEASE(S): Adenocarcinoma,Colon Signet Ring Cell Adenocarcinoma,Stage Ivb Colon Cancer,Carcinoma,Carcinoma, Signet Ring Cell,Recurrent Colon Carcinoma,Colon Mucinous Adenocarcinoma,Stage Iiia Rectal Cancer,Rectal Signet Ring Cell Adenocarcinoma,Recurrent Rectal Carcinoma,Stage Iiib Rectal Cancer,Stage Iiib Colon Cancer,Stage Iiic Colon Cancer,Rectal Neoplasms,Cystadenocarcinoma,Stage Iiic Rectal Cancer,Stage Iva Rectal Cancer,Rectal Mucinous Adenocarcinoma,Stage Ivb Rectal Cancer,Adenocarcinoma, Mucinous,Stage Iva Colon Cancer,Colonic Neoplasms,Stage Iiia Colon Cancer

PROVIDER: 2140889 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR